Tests risankizumab in children with moderately to severely active Crohn's disease
Tests risankizumab in children with Crohn's disease who did not respond well to other treatments.
Key facts
- Who runs it
- AbbVie
- Where
- Aurora, Cleveland, Indianapolis, Little Rock, Minneapolis, Morristown, New York, Oakland, Orlando, Phoenix, and Waltham, United StatesSee the 11 sitesAlso in 20 other countries, 77 sites
- Trial code
- Registry title
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 110 people, planned
- Started
- 11 Dec 2023
- Expected to end
- Apr 2029
- Type of study
- Interventional, 15 groups
- Treatments tested
- Risankizumab
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 2 to under 18 with moderately to severely active Crohn's disease. They must not have done well on, or could not tolerate, other treatments.
- Age
- 2 to under 18 years (record lists 2 Years to 17 Years)
- Sex
- All sexes can join.
- Disease stage
- Moderately to severely active Crohn's disease: PCDAI score above 30 at Baseline, and signs of inflammation in the bowel lining on endoscopy (SES-CD of 6 or more for ileocolonic or colonic disease, or 4 or more for disease only in the ileum).
- Earlier treatment
- Must have had intolerance or an inadequate response to one or more of these drug groups: aminosalicylates, oral locally acting corticosteroids, systemic steroids, immunomodulators, and/or biologic therapies. Aminosalicylates alone are not enough in France, Italy, the Netherlands, Spain and Sweden.
Main reasons for not taking part
- Ulcerative colitis, indeterminate colitis or monogenic IBD
- Crohn's disease diagnosed before 2 years of age
- Known or suspected primary immunodeficiency
- Ostomy or ileoanal pouch, or short bowel syndrome
- Bowel resection surgery in the 3 months before Baseline, or more than 3 bowel resections
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Pediatric individuals, 2 to < 18 years old
- Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
- Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
- Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies
Who cannot take part
- Any of the following medical disorders:; Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD; A diagnosis of CD prior to 2 years of age; A diagnosis or suspected diagnosis of a primary immunodeficiency; Currently known complications of CD such as:; Active abscess (abdominal or perianal); Symptomatic bowel strictures; > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum; Fulminant colitis; Toxic megacolon; Or any other manifestation that might require surgery while enrolled in the study; Ostomy or ileoanal pouch; Diagnosis of short gut or short bowel syndrome; Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections
- History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
Where in United States
Also in 20 other countries, 77 sites
- Children's Hospital Colorado - Aurora /ID# 255764Aurora, United StatesTaking people
- Cleveland Clinic - Cleveland /ID# 256453Cleveland, United StatesContact: Site CoordinatorTaking people
- Indiana University Health Riley Hospital for Children /ID# 256454Indianapolis, United StatesTaking people
- Arkansas Children's Hospital /ID# 255762Little Rock, United StatesNo longer taking part
- MNGI Digestive Health, P. A. /ID# 255366Minneapolis, United StatesTaking people
- Goryeb Childrens Hospital /ID# 256452Morristown, United StatesTaking people
- Icahn School of Medicine at Mount Sinai /ID# 254880New York, United StatesTaking people
- UCSF Benioff Children's Hospital - Oakland /ID# 258327Oakland, United StatesTaking people
- Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437Orlando, United StatesTaking people
- Phoenix Children's Hospital /ID# 255766Phoenix, United StatesTaking people
- Massachusetts General Hospital - Mass General Waltham /ID# 255767Waltham, United StatesTaking people
About the trial
What the trial wants to find out
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.
Read full original descriptionShow less
Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.
Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
The 15 groups in the trial
- PK Cohort 1: SS1Treatment being tested
Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.
Treatment: Risankizumab
- PK Cohort 1: SS2 Dose ATreatment being tested
Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Treatment: Risankizumab
- PK Cohort 1: SS2 Dose BTreatment being tested
Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Treatment: Risankizumab
- PK Cohort 1: SS3 Dose ATreatment being tested
Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Treatment: Risankizumab
- PK Cohort 1: SS3 Dose BTreatment being tested
Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Treatment: Risankizumab
- PK Cohort 2: SS1Treatment being tested
Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
Treatment: Risankizumab
- PK Cohort 2: SS2 Dose ATreatment being tested
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Treatment: Risankizumab
- PK Cohort 2: SS2 Dose BTreatment being tested
Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Treatment: Risankizumab
- PK Cohort 2: SS3 Dose ATreatment being tested
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Treatment: Risankizumab
- PK Cohort 2: SS3 Dose BTreatment being tested
Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Treatment: Risankizumab
- Expansion Cohort 3: SS1Treatment being tested
Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.
Treatment: Risankizumab
- Expansion Cohort 3: SS2 Dose ATreatment being tested
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Treatment: Risankizumab
- Expansion Cohort 3: SS2 Dose BTreatment being tested
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
Treatment: Risankizumab
- Expansion Cohort 3: SS3 Dose ATreatment being tested
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Treatment: Risankizumab
- Expansion Cohort 3: SS3 Dose BTreatment being tested
Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Treatment: Risankizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Crohn's Disease
- Plain-language title
- Tests risankizumab in children with moderately to severely active Crohn's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05995353, who can take part
- Record updated
- 20 October 2026